Atrion Corporation

NasdaqGS:ATRI 株式レポート

時価総額：US$809.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Atrion 将来の成長

Future 基準チェック /06

現在、 Atrionの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長16.1%
収益成長率n/a
将来の株主資本利益率n/a
アナリストカバレッジ

None

最終更新日n/a

今後の成長に関する最新情報

Recent updates

分析記事 • May 22

There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings

Soft earnings didn't appear to concern Atrion Corporation's ( NASDAQ:ATRI ) shareholders over the last week. We did...
Seeking Alpha • Mar 24

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

Summary Atrion Corporation, a healthcare company focused on fluid delivery products, has experienced a decline in revenue, profits, and cash flows. The drop in sales of fluid delivery products, which account for 42% of overall revenue, has severely impacted the company's top line. Despite the potential for improvement in the future, the stock is currently expensive compared to similar companies, warranting a cautious outlook and a downgrade to a 'sell' rating. Read the full article on Seeking Alpha
分析記事 • Mar 23

Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%

Atrion Corporation ( NASDAQ:ATRI ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Feb 09

Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jan 04

Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up

Those holding Atrion Corporation ( NASDAQ:ATRI ) shares would be relieved that the share price has rebounded 26% in the...
分析記事 • Sep 14

Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jul 18

Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
分析記事 • Apr 19

Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
分析記事 • Oct 18

Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Seeking Alpha • Sep 08

Atrion: Attractively Priced For Exposure To Defensive Healthcare

Summary Artrion Corp. looks well positioned to continue delivering stable, predictable future cash flows. The stock is ideal for those seeking defensive characteristics into equity portfolios. Shares look attractively priced by our estimate of fair value. We rate ATRI a buy on a $632 valuation. Investment Summary Defensive healthcare looks well positioned to catch a bid in the current investment landscape as investors turn to factors of quality and resiliency. Earnings quality and fundamental momentum are paramount to overcome the deep drawdowns experienced across equity markets in FY22. With that, we look to Atrion Corporation (ATRI), a low volatility offering with extensive business history and deep customer networks. ATRI is ideal for investors seeking to add a defensive overlay to equity portfolios, and shares look attractively priced by our estimation. There's also the $2.15 recently declared dividend [+10.3% YoY] that is not discussed here. We rate ATRI a buy $632 price target. Atrion Q2 earnings: in-line with mature growth cycle ATRI came in with a strong set of numbers once again, with top-line growth of 14% printing quarterly revenue of $48.9 million ("mm"). The bolus of upside was driven by a 37% YoY gain in cardiovascular revenues, and 'other' revenues of 14%, offset by weakness in fluid delivery and ophthalmology, as seen in Exhibit 1. Meanwhile, COGS saw a 13% YoY gain due to the higher revenue volumes, whereas inventories lifted by ~690bps YoY. The spike in inventory value was driven by a 13% increase in raw material value, in-line with market trends and the commodity bull run of the past 12 months. This resulted in a gross profit of $20.8mm, up 16.6% YoY on a gross margin of 42.6%. Exhibit 1. The cardiovascular business continues to be the major performer on a sequential basis. Revenue split continues to shift toward a more even distribution towards cardiovascular. Cardiovascular margin is now ~37% of turnover in Q2 FY22. Note: Adapted from ATRI Q2 FY22 10-Q (Image: HB Insights. Data: ATRI) As seen in Exhibit 2, quarterly operating trends have been consistently buoyant for ATRI from FY15-date. Both turnover and operating profit have ticked up from low-points during the pandemic, whereas FCF [net of dividends] has been narrowing from FY20-date. We note the QoQ decline in FCF yield that investors have realized over this time, which, at face value looks to be quite alarming. Exhibit 2. Quarterly operating metrics demonstrate the resiliency on offer, with sales and pre-tax earnings both lifting back above pre-pandemic levels. Noted is the declining FCF yield on tighter FCF conversion, however, as we discuss below, this is coupled with favorable return on investment to justify the case. Note: [All earnings figures in $mm or %]. Quarterly operating measures are plotted against TTM FCF yield to observe effect of invested capital and return on invested capital. Calculations are made from GAAP earnings with no reconciliations. (Image: HB Insights; Data: ATRI SEC Filings) In light of the tightening FCF and FCF yields our findings illustrate that ATRI's return on investment has remained in the double digits across the examination period. Whilst FCF [net of dividends] has narrowed sequentially, ROIC has remained high and curled up since late FY21 on a TTM basis, as seen in Exhibit 3. This tells us the company is amid a strong capital budgeting cycle that has seen it invest more than it made during the period [in Q2 FY22 in particular]. The combination of negative FCF and rising return on investment is a favorable combination that is incredibly attractive in the current climate. Exhibit 3. Despite tightening FCF and realized FCF yields since FY15, ATRI continuously delivers double-digit return on investment that comfortably outpaces the WACC hurdle of 5% by ~2.8 turns. Note: All figures are in $mm or %. Invested capital is calculated with capitalized R&D investment from the income statement. (Image: HB Insights. Data: ATRI SEC filings) Valuation Shares are trading at 32x trailing earnings, ahead of the sector median's 26.6x. The stock is also priced at 4.5x book value, again a step above the sector's 2.2x. We need to understand what we're buying in ATRI. Valuation is a combination of investment, return on investment and earnings by our estimate - what's real, and what's expected.
分析記事 • Aug 27

Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's

The board of Atrion Corporation ( NASDAQ:ATRI ) has announced that it will be paying its dividend of $2.15 on the 30th...
Seeking Alpha • Aug 22

Atrion raises dividend 10.3% to $2.15/share

Atrion (NASDAQ:ATRI) declares $2.15/share quarterly dividend, 10.3% increase from prior dividend of $1.95. Forward yield 1.38% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See ATRI Dividend Scorecard, Yield Chart, & Dividend Growth.
分析記事 • Jul 18

Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
分析記事 • Jan 03

Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • Nov 18

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation ( NASDAQ:ATRI ) will increase its dividend on the 15th of December to US$1.95. This takes the annual...
分析記事 • Sep 03

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation's ( NASDAQ:ATRI ) dividend will be increasing to US$1.95 on 30th of September. This takes the annual...

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Atrion は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NasdaqGS:ATRI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/2024182132839N/A
3/31/202417719927N/A
12/31/202316919-220N/A
9/30/202316921-199N/A
6/30/202317127-2114N/A
3/31/202317630-1221N/A
12/31/202218435-529N/A
9/30/202218135939N/A
6/30/2022179341741N/A
3/31/2022173342343N/A
12/31/2021165332339N/A
9/30/2021157322139N/A
6/30/2021148311536N/A
3/31/2021143311234N/A
12/31/2020148321739N/A
9/30/2020150331535N/A
6/30/2020155351838N/A
3/31/2020157362242N/A
12/31/2019155372242N/A
9/30/2019156362747N/A
6/30/2019156362746N/A
3/31/2019155352846N/A
12/31/2018152342643N/A
9/30/2018152352843N/A
6/30/2018150343648N/A
3/31/201814735N/A47N/A
12/31/201714737N/A47N/A
9/30/201714634N/A46N/A
6/30/201714633N/A43N/A
3/31/201714631N/A40N/A
12/31/201614328N/A37N/A
9/30/201614328N/A38N/A
6/30/201614228N/A38N/A
3/31/201614428N/A40N/A
12/31/201514629N/A40N/A
9/30/201514629N/A38N/A
6/30/201514529N/A34N/A
3/31/201514328N/A32N/A
12/31/201414128N/A31N/A
9/30/201414028N/A32N/A
6/30/201413728N/A35N/A
3/31/201413527N/A36N/A
12/31/201313227N/A37N/A
9/30/201312926N/A33N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATRIの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ATRIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ATRIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ATRIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ATRIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATRIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2024/08/21 17:21
終値2024/08/21 00:00
収益2024/06/30
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Atrion Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1

アナリスト機関
Norbert KalliwodaDr. Kalliwoda Research